The estimation of body surface area is based on nomograms or computer programs that contain the Du Bois and Du Bois formula or similar formulas. This practice has been handed down through generations of clinical oncologists.
Why do we still use body surface area? Hippocrates is credited with instructing us to do no harm. It is one of our deepest desires to benefit our patients when we prescribe drugs and not to cause harm. This is exceedingly difficult with a group of drugs that have a very narrow therapeutic index, such as anticancer drugs. In our quest to reduce variability in drug response among patients, we seek to reduce the variation in drug exposure. Drug doses that are "calculated" on the basis of body surface area give us a sense of accuracy and safety. However, in the experience of any practicing oncologist, pharmacokinetic and pharmacodynamic variability among patients remains great.
Is the continued use of body surface area based on scientific data and, therefore, rational? The work by Baker et al. (2) in this issue of the Journal suggests no on both counts. For the 33 investigational agents, body surface area-based dosing statistically significantly reduced the interpatient variability in drug clearance for only five drugs, namely docosahexaenoic acidpaclitaxel, 5-fluorouracil/eniluracil, paclitaxel, temozolomide, and troxacitabine. The authors point out that for the handful of drugs for which clearance was associated with body surface area, the relative reduction in variability of clearance was between 15% and 35%; thus, only up to one-third of the total variability could be explained by body surface area. For the agents for which body surface area was associated with clearance, the authors suggest a potential relationship with blood volume or glomerular filtration rate. Furthermore, in the case of paclitaxel, they point to the vehicle (Cremophor EL) that is used in the formulation of the drug as having an impact on the phar- macokinetics. This vehicle has a distribution volume that approximates the blood volume, and body surface area is a covariate for Cremophor EL clearance. In addition, it should be pointed out that even if clearance is related to body surface area, this relationship is clinically meaningless if clearance does not explain variability in drug response. Indeed, no convincing scientific data exist to link the clearance of paclitaxel to its toxic effects.
Are the results of Baker et al. consistent with the literature? Reviews by Reilly and Workman (7) and Gurney (5) suggest that the routine use of body surface area for dose calculation should be re-evaluated and that other methods of dose calculation should be investigated. In an editorial on the topic of body surface area-based dosing of anticancer agents, Ratain (8) posed the question "science, myth, or habit?" and concluded that myth and habit have gotten in the way of science.
How urgently should we reconsider our practice of using body surface area? Recently, the safety of drug dosing has become a concern, even for drugs that produce therapeutic effects at doses far lower than those that cause toxicity. Errors in dose calculation of anticancer agents are even a greater concern because of the high incidence of serious or even life-threatening toxicity associated with many of them. There are many steps involved in giving anticancer drugs, including the calculation of body surface area using height and weight, the calculation of the total dose based on body surface area, the preparation of the agent in the pharmacy, and the administration of the agent by the chemotherapy nurses. Therefore, the advantages of using a fixed or standard dose as opposed to a body surface area-based dose for anticancer drugs become obvious. Errors in calculations and transcriptions could be reduced. Pharmacies would have to store, handle, and deliver fewer unit sizes of anticancer drugs, which would result in greater efficiency. It is also perceivable that this practice would result in cost savings. For oral anticancer drugs, the adherence by patients could be improved (for instance, patients would not have to count out one 50 mg plus two 10 mg tablets for a total daily dose of 70 mg).
Where should we go from here? Even if we do not abandon the use of body surface area when we scale a dose from mouse to humans for phase I studies, we should discontinue the use of body surface area to determine drug doses for patients. The variability in body surface area from mouse to humans is far greater than it is among patients. We should also investigate the reduction of variability by using measurements of renal and hepatic function. The dosing of carboplatin based on estimated creatinine clearance is a good example. It is likely that we will find that genetically determined polymorphisms in drugmetabolizing enzymes in the liver are more important than body surface area in predicting clinical response. Pharmacologically based dosing or specific pharmacogenetically based dosing may be far more rewarding than body surface area-based dosing.
Baker et al. have provided scientific evidence that body surface area-based dosing has very limited utility. This should serve as a challenge to us to find alternative dosing strategies for anticancer agents.
